CYTK - Cytokinetics, Incorporated

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
+0.05 (+0.64%)
As of 9:44AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close7.78
Bid7.75 x 1300
Ask8.63 x 900
Day's Range7.78 - 7.87
52 Week Range6.21 - 15.05
Avg. Volume286,996
Market Cap427.737M
Beta (3Y Monthly)2.27
PE Ratio (TTM)N/A
EPS (TTM)-2.42
Earnings DateNov 1, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est13.83
Trade prices are not sourced from all markets
  • GlobeNewswire18 hours ago

    Cytokinetics to Announce Third Quarter Results on November 1, 2018

    Cytokinetics, Incorporated (CYTK) today announced that it is scheduled to report third quarter results on November 1, 2018 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics’ senior management will host a conference call at 4:30 PM Eastern Time to discuss operational and financial results and the company’s outlook for the future. The conference call will be simultaneously webcast and can be accessed from the homepage and in the Investors & Media section of Cytokinetics’ website at

  • GlobeNewswire3 days ago

    Cytokinetics Unveils Expanded Development Pipeline and Provides Key Updates on Late-Stage Clinical Research Programs at R&D Day

    Cytokinetics, Incorporated (CYTK) plans to present an expansion of its development pipeline with the progression of two additional cardiac muscle directed drug candidates towards first-in-human clinical trials, at an R&D Day today in New York. The first, a novel cardiac troponin activator, discovered under its joint research program with Amgen, was the subject of an Investigational New Drug Application (IND) that Amgen recently filed with the Food & Drug Administration (FDA).

  • GlobeNewswire10 days ago

    Report: Developing Opportunities within Denny's, Cytokinetics, Beazer Homes, Heidrick & Struggles International, Equity Commonwealth, and Spok — Future Expectations, Projections Moving into 2018

    NEW YORK, Oct. 09, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Benzinga11 days ago

    The Week Ahead In Biotech: Conferences, Clinical Trial Results And IPOs

    As we step into the final quarter of 2018, biotech stocks have recorded double-digit gains for the year-to-date period. Will the run up continue? Stay tuned to the following events of the upcoming week. ...

  • GlobeNewswire14 days ago

    Cytokinetics and Astellas Provide Updates Regarding Collaborative Skeletal Muscle Program

    Cytokinetics, Incorporated (Nasdaq: CYTK, “Cytokinetics”) and Astellas Pharma Inc. (TSE: 4503, “Astellas”) today provided an update for their collaborative skeletal muscle program, including clinical trial updates for reldesemtiv in neuromuscular and non-neuromuscular conditions. In addition to reldesemtiv, the companies are advancing another fast skeletal muscle troponin activator (FSTA) into Investigational New Drug (IND)-enabling studies and continuing their joint research program through 2019. Cytokinetics has been developing reldesemtiv as a potential treatment for people with Spinal Muscular Atrophy (SMA), Amyotrophic Lateral Sclerosis (ALS), and other debilitating neuromuscular diseases and conditions associated with skeletal muscle weakness and/or fatigue.

  • GlobeNewswire17 days ago

    Cytokinetics to Host R&D Day on October 16, 2018

    Cytokinetics, Incorporated (CYTK), today announced that it will host an R&D Day on Tuesday, October 16, 2018 from 8:30 AM to 12:30 PM ET at the Parker New York Hotel in New York City. Members of Cytokinetics’ senior management will be joined by expert clinicians to provide new updates to the pipeline and review current clinical programs.

  • Simply Wall St.18 days ago

    Cytokinetics Incorporated (NASDAQ:CYTK): Risks You Need To Consider Before Buying

    If you’re interested in Cytokinetics Incorporated (NASDAQ:CYTK), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could impact Read More...

  • GlobeNewswire24 days ago

    Cytokinetics to Present at the Cantor Fitzgerald Global Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., Sept. 25, 2018-- Cytokinetics, Inc. today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to present a corporate update at the Cantor Fitzgerald ...

  • Benzinga28 days ago

    Cantor Fitzgerald's 7 Buys For 7 Biotechs

    Cantor Fitzgerald has high hopes for patients with rare and orphan diseases.  “We believe that biotech has entered a golden age of innovation and productivity across many therapeutic areas,” the firm said ...

  • Benzingalast month

    The Week Ahead In Biotech (Sept. 16-22): Conferences, PDUFA Dates, Clinical Trial Results And IPOs

    Biotech were trending mostly sideways in the week ending Sept. 14 after posting weekly gains in the previous two weeks. Notwithstanding the overall muted sentiment, there was some activity in reaction ...

  • GlobeNewswirelast month

    Cytokinetics to Present at the Morgan Stanley Global Healthcare Conference

    Cytokinetics, Inc. (CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to present a corporate update at the 16th Annual Morgan Stanley Global Healthcare Conference on Wednesday, September 12, 2018 at 11:40 AM ET at the Grant Hyatt in New York City. The webcast replay of the presentation will be archived on the Presentations page within the Investors & Media section of Cytokinetics’ website for 90 days following the conclusion of the event. Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining.

  • GlobeNewswire2 months ago

    Cytokinetics Awards Inaugural Communications Fellowship To The ALS Association Golden West Chapter

    Cytokinetics, Incorporated (CYTK) today announced that The ALS Association Golden West Chapter is the inaugural recipient of the Cytokinetics Communications Fellowship, an annual grant from the company intended to support increased capacity and community engagement for nonprofit organizations. “As a longstanding partner of the disease and patient advocacy community, we recognized a need for organizations to expand the scope of their communications to support families with rare diseases of muscle dysfunction and we sought an opportunity to close that gap,” said Diane Weiser, Cytokinetics’ Vice President of Corporate Communications and Investor Relations. “We are extremely grateful to Cytokinetics and honored to receive this unique grant,” said Fred Fisher, MSW, President and CEO of The ALS Association Golden West Chapter.

  • Benzinga3 months ago

    Cytokinetics Downgraded On Data Delay

    Biopharma Cytokinetics Inc. (NASDAQ: CYTK ) announced a delay in drug studies during its earnings call Thursday, prompting a downgrade by Morgan Stanley.  The Analysts Morgan Stanley's Matthew Harrison ...

  • GlobeNewswire3 months ago

    Market Trends Toward New Normal in US Foods Holding, Limelight Networks, Ladenburg Thalmann Financial Services, MPLX LP, Cytokinetics, and FuelCell Energy — Emerging Consolidated Expectations, Analyst Ratings

    NEW YORK, Aug. 01, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of US ...

  • Thomson Reuters StreetEvents3 months ago

    Edited Transcript of CYTK earnings conference call or presentation 26-Jul-18 8:30pm GMT

    Q2 2018 Cytokinetics Inc Earnings Call

  • Associated Press3 months ago

    Cytokinetics: 2Q Earnings Snapshot

    The South San Francisco, California-based company said it had a loss of 51 cents per share. The results missed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...

  • GlobeNewswire3 months ago

    Cytokinetics, Inc. Reports Second Quarter 2018 Financial Results

    Phase 2 Study of Reldesemtiv in Patients with SMA Showed Potentially Clinically Meaningful Effects on Six Minute Walk Distance and Maximal Expiratory Pressure. Results from Phase 2 Clinical Trial of Reldesemtiv ...

  • SmarterAnalyst4 months ago

    3 Biotechs with Upcoming Data to Watch

    Cytokinetics (NASDASQ:CYTK) looks to turn around their fortunes following last year’s unsuccessful readout of Tirasemtiv in ALS. The company’s follow on asset Reldesemtiv, is built on the same mechanism but looks to resolve the dropout issue. Further, the drug seems to be more potent than its predecessor, which may help amplify the signal we saw in respiratory function.

  • June Best Growth Stocks
    Simply Wall St.4 months ago

    June Best Growth Stocks

    Looking to add potential meaningful upside to your portfolio, but unsure where to start? Stocks such as Globant and Cytokinetics are considered to be high growth in terms of howRead More...

  • Are Options Traders Betting on a Big Move in Cytokinetics (CYTK) Stock?
    Zacks4 months ago

    Are Options Traders Betting on a Big Move in Cytokinetics (CYTK) Stock?

    Investors in Cytokinetics (CYTK) need to pay close attention to the stock based on moves in the options market lately.